Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis

Abstract Background Risankizumab was an approved novel drug by Japan for psoriasis, we aimed to explore its underlying therapeutic mechanism through the single-cell RNA sequencing (scRNA-seq) technology. Methods ScRNA-seq data (GSE228421) were obtained from the Gene Expression Omnibus (GEO) database...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Yuan Yuan, Linzi Li, Lihong Yang, Jiyuan Zheng, Guang Gao, Ting Tan, Jing Liu, Wen Sun
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-11-01
Saila:	European Journal of Medical Research
Gaiak:	Risankizumab Psoriasis Pseudo-time analysis Myeloid cells Anti-inflammatory
Sarrera elektronikoa:	https://doi.org/10.1186/s40001-025-03346-0
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!